Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection

Treatment of latent tuberculosis infection (LTBI) is critical to the control and elimination of tuberculosis disease (TB) in the United States. In 2011, CDC recommended a short-course combination regimen of once-weekly isoniazid and rifapentine for 12 weeks (3HP) by directly observed therapy (DOT) f...

Full description

Saved in:
Bibliographic Details
Published in:MMWR. Morbidity and mortality weekly report 2018-06, Vol.67 (25), p.723-726
Main Authors: Borisov, Andrey S., Morris, Sapna Bamrah, Njie, Gibril J., Winston, Carla A., Burton, Deron, Goldberg, Stefan, Woodruff, Rachel Yelk, Allen, Leeanna, LoBue, Philip, Vernon, Andrew
Format: Article
Language:English
Subjects:
Drug therapy
Full Report
HIV
Isoniazid
Patient compliance
Tuberculosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment of latent tuberculosis infection (LTBI) is critical to the control and elimination of tuberculosis disease (TB) in the United States. In 2011, CDC recommended a short-course combination regimen of once-weekly isoniazid and rifapentine for 12 weeks (3HP) by directly observed therapy (DOT) for treatment of LTBI, with limitations for use in children aged
ISSN:0149-2195
1545-861X
DOI:10.15585/mmwr.mm6725a5